Carsten Denkert

List of Publications by Year
in descending order

209 papers	24,526 citations	15466 65 h-index	7931 149 g-index
214 all docs	214 docs citations	214 times ranked	24217 citing authors

#	Article	IF	Citations
1	Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes. Journal of Clinical Oncology, 2012, 30, 1796-1804.	0.8	2,062
2	Pembrolizumab for Early Triple-Negative Breast Cancer. New England Journal of Medicine, 2020, 382, 810-821.	13.9	1,542
3	Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer. Journal of Clinical Oncology, 2010, 28, 105-113.	0.8	1,438
4	Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncology, The, 2018, 19, 40-50.	5.1	1,327
5	Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization. PLoS ONE, 2012, 7, e51862.	1.1	983
6	Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers. Journal of Clinical Oncology, 2015, 33, 983-991.	0.8	863
7	Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncology, The, 2014, 15, 747-756.	5.1	810
8	Breast cancer. Lancet, The, 2021, 397, 1750-1769.	6.3	731
9	Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nature Reviews Clinical Oncology, 2016, 13, 228-241.	12.5	679
10	Molecular alterations in triple-negative breast cancer—the road to new treatment strategies. Lancet, The, 2017, 389, 2430-2442.	6.3	640
11	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. Advances in Anatomic Pathology, 2017, 24, 311-335.	2.4	530
12	Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. Journal of Clinical Oncology, 2019, 37, 559-569.	0.8	505
13	Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab. JAMA Oncology, 2015, 1, 448.	3.4	482
14	Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer. New England Journal of Medicine, 2012, 366, 299-309.	13.9	473
15	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. Advances in Anatomic Pathology, 2017, 24, 235-251.	2.4	469
16	Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. New England Journal of Medicine, 2022, 386, 556-567.	13.9	444
17	Mass Spectrometry–Based Metabolic Profiling Reveals Different Metabolite Patterns in Invasive Ovarian Carcinomas and Ovarian Borderline Tumors. Cancer Research, 2006, 66, 10795-10804.	0.4	366
18	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Annals of Oncology, 2021, 32, 1216-1235.	0.6	354

#	Article	IF	Citations
19	Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group. Journal of the National Cancer Institute, 2021, 113, 808-819.	3.0	319
20	Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial. Lancet Oncology, The, 2016, 17, 345-356.	5.1	316
21	Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer. Seminars in Cancer Biology, 2018, 52, 16-25.	4.3	303
22	Response-Guided Neoadjuvant Chemotherapy for Breast Cancer. Journal of Clinical Oncology, 2013, 31, 3623-3630.	0.8	302
23	Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer. JAMA Oncology, 2017, 3, 1378.	3.4	300
24	Metabolite profiling of human colon carcinoma — deregulation of TCA cycle and amino acid turnover. Molecular Cancer, 2008, 7, 72.	7.9	285
25	Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncology, The, 2021, 22, 1151-1161.	5.1	248
26	Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor—Positive Breast Cancer. JAMA Oncology, 2018, 4, 545.	3.4	246
27	Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group. Modern Pathology, 2016, 29, 1155-1164.	2.9	230
28	Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget, 2016, 7, 1486-1499.	0.8	212
29	The landscape of metastatic progression patterns across major human cancers. Oncotarget, 2015, 6, 570-583.	0.8	208
30	Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. Modern Pathology, 2015, 28, 1185-1201.	2.9	205
31	Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer, 2003, 97, 2978-2987.	2.0	197
32	Expression of Cyclooxygenase 2 Is an Independent Prognostic Factor in Human Ovarian Carcinoma. American Journal of Pathology, 2002, 160, 893-903.	1.9	183
33	Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy. Journal of the National Cancer Institute, 2016, 108, djw149.	3.0	165
34	Expression of the ELAV-like protein HuR in human colon cancer: association with tumor stage and cyclooxygenase-2. Modern Pathology, 2006, 19, 1261-1269.	2.9	161
35	Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer. Clinical Cancer Research, 2016, 22, 5747-5754.	3.2	158
36	Overexpression of the Embryonic-Lethal Abnormal Vision-like Protein HuR in Ovarian Carcinoma Is a Prognostic Factor and Is Associated with Increased Cyclooxygenase 2 Expression. Cancer Research, 2004, 64, 189-195.	0.4	153

#	Article	IF	Citations
37	Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancerâ€"The Penelope-B Trial. Journal of Clinical Oncology, 2021, 39, 1518-1530.	0.8	153
38	Expression of the ELAV-Like Protein HuR Is Associated with Higher Tumor Grade and Increased Cyclooxygenase-2 Expression in Human Breast Carcinoma. Clinical Cancer Research, 2004, 10, 5580-5586.	3.2	142
39	The path to a better biomarker: application of a risk management framework for the implementation of PDâ€‘1 and TILs as immunoâ€‘oncology biomarkers in breast cancer clinical trials and daily practice. Journal of Pathology, 2020, 250, 667-684.	2.1	142
40	Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer. Clinical Cancer Research, 2013, 19, 4521-4531.	3.2	137
41	Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial. BMC Medicine, 2018, 16, 179.	2.3	134
42	Strategies for developing Ki67 as a useful biomarker in breast cancer. Breast, 2015, 24, S67-S72.	0.9	130
43	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. Npj Breast Cancer, 2021, 7, 150.	2.3	112
44	Tumor infiltrating lymphocytes in early breast cancer. Breast, 2018, 37, 207-214.	0.9	108
45	A prognostic gene expression index in ovarian cancerâ€"validation across different independent data sets. Journal of Pathology, 2009, 218, 273-280.	2.1	107
46	Expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) in primary human ovarian carcinoma. International Journal of Cancer, 2002, 102, 507-513.	2.3	106
47	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. Npj Breast Cancer, 2020, 6, 17.	2.3	106
48	Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2021, 39, 506-506.	0.8	96
49	KRAS Genotyping of Paraffin-Embedded Colorectal Cancer Tissue in Routine Diagnostics. Journal of Molecular Diagnostics, 2010, 12, 35-42.	1.2	94
50	Classical pathology and mutational load of breast cancer â€" integration of two worlds. Journal of Pathology: Clinical Research, 2015, 1, 225-238.	1.3	91
51	Induction of G0/G1 cell cycle arrest in ovarian carcinoma cells by the anti-inflammatory drug NS-398, but not by COX-2-specific RNA interference. Oncogene, 2003, 22, 8653-8661.	2.6	90
52	Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. Npj Breast Cancer, 2020, 6, 16.	2.3	90
53	Metabolomics of human breast cancer: new approaches for tumor typing and biomarker discovery. Genome Medicine, 2012, 4, 37.	3.6	88
54	Decentral gene expression analysis for ER+/Her2â€° breast cancer: results of a proficiency testing program for the EndoPredict assay. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 460, 251-259.	1.4	88

#	Article	IF	Citations
55	Quantitative Determination of Estrogen Receptor, Progesterone Receptor, and HER2 mRNA in Formalin-fixed Paraffin-embedded Tissueâ€"A New Option for Predictive Biomarker Assessment in Breast Cancer. Diagnostic Molecular Pathology, 2011, 20, 1-10.	2.1	87
56	Standardized Ki67 Diagnostics Using Automated Scoringâ€"Clinical Validation in the GeparTrio Breast Cancer Study. Clinical Cancer Research, 2015, 21, 3651-3657.	3.2	85
57	Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). European Journal of Cancer, 2017, 85, 133-145.	1.3	84
58	Intense dose-dense epirubicin, paclitaxel, cyclophosphamideÂversus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOctoâ€"GBG 84): A randomised phase III trial. European Journal of Cancer, 2019, 106, 181-192.	1.3	84
59	Co-expression of MET and CD47 is a novel prognosticator for survival of luminal-type breast cancer patients. Oncotarget, 2014, 5, 8147-8160.	0.8	83
60	Panâ€cancer analysis of copy number changes in programmed deathâ€ligand 1 (PDâ€L1, CD274) â€" associations with gene expression, mutational load, and survival. Genes Chromosomes and Cancer, 2016, 55, 626-639.	1.5	80
61	An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer. Modern Pathology, 2019, 32, 59-69.	2.9	78
62	Accumulated Metabolites of Hydroxybutyric Acid Serve as Diagnostic and Prognostic Biomarkers of Ovarian High-Grade Serous Carcinomas. Cancer Research, 2016, 76, 796-804.	0.4	74
63	Cytotoxic tumour-infiltrating T lymphocytes influence outcome in resected pancreatic ductal adenocarcinoma. European Journal of Cancer, 2017, 83, 290-301.	1.3	74
64	Morphological and molecular breast cancer profiling through explainable machine learning. Nature Machine Intelligence, 2021, 3, 355-366.	8.3	72
65	Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment. Cell Death and Differentiation, 2021, 28, 2778-2796.	5.0	72
66	Prognostic Impact of Cyclooxygenase-2 in Breast Cancer. Clinical Breast Cancer, 2004, 4, 428-433.	1.1	68
67	The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical Decisions. PLoS ONE, 2013, 8, e68252.	1.1	66
68	Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer. BMC Clinical Pathology, 2015, 15, 20.	1.8	61
69	Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden. OncoImmunology, 2018, 7, e1526613.	2.1	60
70	Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 527-537.	3.3	59
71	Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences. Oncotarget, 2014, 5, 9952-9965.	0.8	58
72	pT but not pN stage of the 8th TNM classification significantly improves prognostication in pancreatic ductal adenocarcinoma. European Journal of Cancer, 2017, 84, 121-129.	1.3	57

#	Article	IF	Citations
73	High-grade ovarian serous carcinoma patients exhibit profound alterations in lipid metabolism. Oncotarget, 2017, 8, 102912-102922.	0.8	57
74	PD-L1 (CD274) copy number gain, expression, and immune cell infiltration as candidate predictors for response to immune checkpoint inhibitors in soft-tissue sarcoma. OncoImmunology, 2017, 6, e1279777.	2.1	50
75	Role of *TP53* mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy. Oncotarget, 2016, 7, 67686-67698.	0.8	50
76	Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox. Lancet Oncology, The, 2021, 22, e18-e28.	5.1	49
77	An inhibitor of stress-activated MAP-kinases reduces invasion and MMP-2 expression of malignant melanoma cells. Clinical and Experimental Metastasis, 2002, 19, 79-85.	1.7	47
78	Matrix stiffness drives stromal autophagy and promotes formation of a protumorigenic niche. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	47
79	Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy. European Journal of Cancer, 2016, 53, 65-74.	1.3	46
80	FGFR4 overexpression and hotspot mutations in metastatic ER+ breast cancer are enriched in the lobular subtype. Npj Breast Cancer, 2019, 5, 19.	2.3	46
81	Metaplastic breast cancers: Genomic profiling, mutational burden and tumor-infiltrating lymphocytes. Breast, 2019, 44, 29-32.	0.9	46
82	Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer. BMC Medicine, 2015, 13, 177.	2.3	45
83	Loss of *ARID1A* Activates *ANXA1*, which Serves as a Predictive Biomarker for Trastuzumab Resistance. Clinical Cancer Research, 2016, 22, 5238-5248.	3.2	43
84	Acquired mutations and transcriptional remodeling in long-term estrogen-deprived locoregional breast cancer recurrences. Breast Cancer Research, 2021, 23, 1.	2.2	43
85	Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC).. Journal of Clinical Oncology, 2018, 36, 104-104.	0.8	43
86	Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer. JAMA Oncology, 2020, 6, 744.	3.4	42
87	Does long-term survival in patients with pancreatic cancer really exist?-Results from the CONKO-001 study. Journal of Surgical Oncology, 2013, 108, 398-402.	0.8	41
88	Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer. Clinical Cancer Research, 2016, 22, 2675-2683.	3.2	41
89	Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors â€" An analysis of 2765 patients from neoadjuvant clinical trials. European Journal of Cancer, 2021, 148, 159-170.	1.3	41
90	Neoadjuvant treatment of breast cancer â€" Clinical and research perspective. Breast, 2015, 24, S73-S77.	0.9	40

#	Article	IF	Citations
91	Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxaneâ€"Anthracycline Containing Chemotherapyâ€"DAFNE (GBG-70). Clinical Cancer Research, 2015, 21, 2924-2931.	3.2	38
92	Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522.. Journal of Clinical Oncology, 2022, 40, 503-503.	0.8	38
93	Relevance of tumour-infiltrating lymphocytes, PD-1 and PD-L1 in patients with high-risk, nodal-metastasised breast cancer of the German Adjuvant Intergroup Nodeâ€"positive study. European Journal of Cancer, 2019, 114, 76-88.	1.3	37
94	Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer. JAMA Oncology, 2021, 7, 603.	3.4	37
95	DNA methylation profiling reliably distinguishes pulmonary enteric adenocarcinoma from metastatic colorectal cancer. Modern Pathology, 2019, 32, 855-865.	2.9	36
96	Mutation patterns in genes encoding interferon signaling and antigen presentation: A panâ€"cancer survey with implications for the use of immune checkpoint inhibitors. Genes Chromosomes and Cancer, 2017, 56, 651-659.	1.5	35
97	Chromosome 9p copy number gains involving PD-L1 are associated with a specific proliferation and immune-modulating gene expression program active across major cancer types. BMC Medical Genomics, 2017, 10, 74.	0.7	35
98	GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HRD).. Journal of Clinical Oncology, 2019, 37, 506-506.	0.8	34
99	Tumor infiltrating lymphocyte stratification of prognostic staging of early-stage triple negative breast cancer. Npj Breast Cancer, 2022, 8, 3.	2.3	33
100	Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. Breast Cancer Research and Treatment, 2018, 167, 59-71.	1.1	32
101	Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial. Clinical Cancer Research, 2019, 25, 3986-3995.	3.2	32
102	KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2018, 36, TPS602-TPS602.	0.8	30
103	Hotspot<i>ESR1</i>Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis. Cancer Research, 2022, 82, 1321-1339.	0.4	30
104	Outcome after neoadjuvant chemotherapy in elderly breast cancer patients - a pooled analysis of individual patient data from eight prospectively randomized controlled trials. Oncotarget, 2018, 9, 15168-15179.	0.8	29
105	Tumour buds determine prognosis in resected pancreatic ductal adenocarcinoma. British Journal of Cancer, 2018, 118, 1485-1491.	2.9	29
106	Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials. Annals of Surgical Oncology, 2019, 26, 3892-3901.	0.7	29
107	A Non-interventional Clinical Trial Assessing Immune Responses After Radiofrequency Ablation of Liver Metastases From Colorectal Cancer. Frontiers in Immunology, 2019, 10, 2526.	2.2	29
108	PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxaneâ€"Based Neoadjuvant Chemotherapy. Cancer Research and Treatment, 2020, 52, 689-696.	1.3	29

#	Article	IF	Citations
109	*TP53* Mutations Predict Sensitivity to Adjuvant Gemcitabine in Patients with Pancreatic Ductal Adenocarcinoma: Next-Generation Sequencing Results from the CONKO-001 Trial. Clinical Cancer Research, 2020, 26, 3732-3739.	3.2	28
110	Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer. Clinical Cancer Research, 2021, 27, 2584-2591.	3.2	27
111	Wilms tumor protein 1 (WT1) â€" Not only a diagnostic but also a prognostic marker in high-grade serous ovarian carcinoma. Gynecologic Oncology, 2016, 140, 494-502.	0.6	26
112	Locoregional recurrence risk after neoadjuvant chemotherapy: A pooled analysis of nine prospective neoadjuvant breast cancer trials. European Journal of Cancer, 2020, 130, 92-101.	1.3	26
113	Tissue-Based Metabolomics to Analyze the Breast Cancer Metabolome. Recent Results in Cancer Research, 2016, 207, 157-175.	1.8	25
114	Clinical relevance and concordance of HER2 status in local and central testingâ€"an analysis of 1581 HER2-positive breast carcinomas over 12 years. Modern Pathology, 2018, 31, 607-615.	2.9	25
115	Overexpression of cyclooxygenase-2 in human prostate carcinoma and prostatic intraepithelial neoplasia-association with increased expression of polo-like kinase-1. Prostate, 2007, 67, 361-369.	1.2	24
116	Prognostic significance of Ki-67 levels and hormone receptor expression in low-grade serous ovarian carcinoma: an investigation of the Tumor Bank Ovarian Cancer Network. Human Pathology, 2019, 85, 299-308.	1.1	24
117	Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer. JAMA Oncology, 2021, 7, 1291.	3.4	24
118	Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer. Neoplasia, 2018, 20, 280-288.	2.3	23
119	A multicentre analytical comparison study of interâ€reader and interâ€assay agreement of four programmed deathâ€ligand 1 immunohistochemistry assays for scoring in tripleâ€negative breast cancer. Histopathology, 2021, 78, 567-577.	1.6	23
120	Ioncopy: a novel method for calling copy number alterations in amplicon sequencing data including significance assessment. Oncotarget, 2016, 7, 13236-13247.	0.8	23
121	Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy. Seminars in Immunopathology, 2011, 33, 341-351.	2.8	22
122	Tumor-infiltrating lymphocytes in breast cancer. OncoImmunology, 2014, 3, e27926.	2.1	21
123	Mutational profiles of Brenner tumors show distinctive features uncoupling urothelial carcinomas and ovarian carcinoma with transitional cell histology. Genes Chromosomes and Cancer, 2017, 56, 758-766.	1.5	21
124	Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy. Breast Cancer Research, 2019, 21, 142.	2.2	21
125	Fulminant Intravascular Disseminating Malignant Melanoma Mimicking Acute Leukemia. Blood, 1999, 94, 1483-1484.	0.6	20
126	P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment. Pathology Research and Practice, 2016, 212, 726-734.	1.0	19

#	ARTICLE	IF	CITATIONS
127	Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC. , 2020, 8, e001261.		18
128	Linking CREB function with altered metabolism in murine fibroblast-based model cell lines. Oncotarget, 2017, 8, 97439-97463.	0.8	18
129	Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study. Modern Pathology, 2022, 35, 1362-1369.	2.9	18
130	Cytokine-suppressive anti-inflammatory drugs (CSAIDs) inhibit invasion and MMP-1 production of ovarian carcinoma cells. Cancer Letters, 2003, 195, 101-109.	3.2	17
131	Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. Npj Breast Cancer, 2020, 6, 15.	2.3	16
132	How VEGF-A and its splice variants affect breast cancer development â€" clinical implications. Cellular Oncology (Dordrecht), 2022, 45, 227-239.	2.1	16
133	Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer. Clinical Cancer Research, 2022, 28, 2587-2597.	3.2	16
134	Integrative proteomic and gene expression analysis identify potential biomarkers for adjuvant trastuzumab resistance: analysis from the Fin-her phase III randomized trial. Oncotarget, 2015, 6, 30306-30316.	0.8	14
135	Comprehensive analysis of clinico-pathological data reveals heterogeneous relations between atherosclerosis and cancer. Journal of Clinical Pathology, 2014, 67, 482-490.	1.0	13
136	Morphomolecular analysis of the immune tumor microenvironment in human head and neck cancer. Cancer Immunology, Immunotherapy, 2019, 68, 1443-1454.	2.0	13
137	Reactive stroma and trastuzumab resistance in HER2â€positive early breast cancer. International Journal of Cancer, 2020, 147, 266-276.	2.3	13
138	Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness. Npj Breast Cancer, 2021, 7, 142.	2.3	13
139	Prediction of Response to Neoadjuvant Chemotherapy: New Biomarker Approaches and Concepts. Breast Care, 2011, 6, 265-272.	0.8	12
140	Morphology and tumourâ€infiltrating lymphocytes in highâ€stage, highâ€grade serous ovarian carcinoma correlated with longâ€term survival. Histopathology, 2018, 73, 1002-1012.	1.6	12
141	Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial. International Journal of Cancer, 2019, 145, 857-868.	2.3	12
142	Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer. European Journal of Cancer, 2022, 160, 100-111.	1.3	12
143	Pathological Response in the Breast and Axillary Lymph Nodes after Neoadjuvant Systemic Treatment in Patients with Initially Node-Positive Breast Cancer Correlates with Disease Free Survival: An Exploratory Analysis of the GeparOcto Trial. Cancers, 2022, 14, 521.	1.7	12
144	Cytokeratin 5/6 expression, prognosis, and association with estrogen receptor Î± in high-grade serous ovarian carcinoma. Human Pathology, 2017, 67, 30-36.	1.1	11

#	Article	IF	Citations
145	Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor. Clinical Cancer Research, 2018, 24, 3358-3365.	3.2	11
146	Hypoxia-mediated alterations and their role in the HER-2/neuregulated CREB status and localization. Oncotarget, 2016, 7, 52061-52084.	0.8	11
147	Prioritization of metabolic genes as novel therapeutic targets in estrogen-receptor negative breast tumors using multi-omics data and text mining. Oncotarget, 2019, 10, 3894-3909.	0.8	11
148	Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIIIâ€‰+â€‰IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial. Breast Cancer Research and Treatment, 2019, 176, 557-568.	1.1	10
149	KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptorâ€“positive, human epidermal growth factor receptor 2â€“negative (ER+/HER2â˜) breast cancer.. Journal of Clinical Oncology, 2019, 37, TPS601-TPS601.	0.8	10
150	A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial. Clinical Cancer Research, 2020, 26, 1896-1904.	3.2	9
151	MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial. PLoS ONE, 2020, 15, e0238021.	1.1	8
152	Interobserver Agreement of PD-L1/SP142 Immunohistochemistry and Tumor-Infiltrating Lymphocytes (TILs) in Distant Metastases of Triple-Negative Breast Cancer: A Proof-of-Concept Study. A Report on Behalf of the International Immuno-Oncology Biomarker Working Group. Cancers, 2021, 13, 4910.	1.7	8
153	HER2-low-positive breast cancer from four neoadjuvant clinical trials â€“ Authors' reply. Lancet Oncology, The, 2021, 22, e427.	5.1	8
154	Hent1 expression in patients with pancreatic cancer treated with gemcitabine after curative intended resection: Results from the CONKO-001 trial.. Journal of Clinical Oncology, 2014, 32, 4124-4124.	0.8	8
155	A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel / carboplatin followed by epirubicin / cyclophosphamide as neoadjuvant chemotherapy in patients with HER2-negative early breast cancer and homologous recombination deficiency (HRD): GeparOLA.. Journal of Clinical Oncology, 2016, 34, TPS1096-TPS1096.	0.8	7
156	APOBEC3B protein expression and mRNA analyses in patients with high-grade serous ovarian carcinoma. Histology and Histopathology, 2019, 34, 405-417.	0.5	7
157	How Much Information Do We Really Need After Neoadjuvant Therapy for Breast Cancer?. Journal of Clinical Oncology, 2017, 35, 1029-1030.	0.8	6
158	PARP-1 expression as a prognostic factor in Desmoid-type fibromatosis. Annals of Diagnostic Pathology, 2020, 44, 151442.	0.6	6
159	Reproducibility of mRNA-Based Testing of ESR1, PGR, ERBB2, and MKI67 Expression in Invasive Breast Cancerâ€”A Europe-Wide External Quality Assessment. Cancers, 2021, 13, 4718.	1.7	6
160	Expression of immunologic genes in triple-negative and HER2-positive breast cancer in the neoadjuvant GEPARSIXTO trial: Prediction of response to carboplatin-based chemotherapy.. Journal of Clinical Oncology, 2014, 32, 510-510.	0.8	6
161	NSABP B-59/GBG 96-GeparDouze: A randomized double-blind phase III clinical trial of neoadjuvant chemotherapy (NAC) with atezolizumab or placebo in Patients (pts) with triple negative breast cancer (TNBC) followed by adjuvant atezolizumab or placebo.. Journal of Clinical Oncology, 2018, 36, TPS603-TPS603.	0.8	6
162	<i>mdm2</i> gene amplification is associated with luminal breast cancer progression in humanized <scp>PDX</scp> mice and a worse outcome of estrogen receptor positive disease. International Journal of Cancer, 2022, 150, 1357-1372.	2.3	6

#	Article	IF	Citations
163	Semiconductor sequencing: how many flows do you need?. Bioinformatics, 2015, 31, 1199-1203.	1.8	5
164	Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus. Geburtshilfe Und Frauenheilkunde, 2021, 81, 637-653.	0.8	5
165	Correlation of <i>PIK3CA</i> mutation with pathological complete response in primary HER2-positive breast cancer: Combined analysis of 967 patients from three prospective clinical trials.. Journal of Clinical Oncology, 2015, 33, 511-511.	0.8	5
166	Immunophenotype and proliferation to predict for response to neoadjuvant chemotherapy in TNBC: Results from BrighTNess phase III study.. Journal of Clinical Oncology, 2019, 37, 510-510.	0.8	5
167	Abstract GS1-01: KEYNOTE-522 study of neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Event-free survival sensitivity and subgroup analyses. Cancer Research, 2022, 82, GS1-01-GS1-01.	0.4	5
168	Biomarkers for response to immunotherapy in triple-negative breast cancer: Differences between survival and pCR biomarkers.. Journal of Clinical Oncology, 2022, 40, 583-583.	0.8	5
169	Ioncopy: an R Shiny app to call copy number alterations in targeted NGS data. BMC Bioinformatics, 2018, 19, 157.	1.2	4
170	SPARC in pancreatic cancer: Results from the CONKO-001 study.. Journal of Clinical Oncology, 2013, 31, 4016-4016.	0.8	4
171	Response-based molecular subtyping—emergence of the third generation of breast cancer subtypes. Cancer Cell, 2022, 40, 592-594.	7.7	4
172	Validation of a Nomogram Predicting Non-Sentinel Lymph Node Metastases among Patients with Breast Cancer after Primary Systemic Therapy - a transSENTINA Substudy. Breast Care, 2018, 13, 440-446.	0.8	3
173	Abstract GS3-01: Investigating denosumab as an add-on treatment to neoadjuvant chemotherapy and two different nab-paclitaxel schedules in a 2x2 design in primary breast cancer - First results of the GeparX study. Cancer Research, 2020, 80, GS3-01-GS3-01.	0.4	3
174	Investigating denosumab as add-on neoadjuvant treatment for hormone receptor-negative, RANK-positive or RANK-negative primary breast cancer and two different nab-Paclitaxel schedules - 2x2 factorial design (GeparX).. Journal of Clinical Oncology, 2016, 34, TPS635-TPS635.	0.8	3
175	Gene expression profiling using Nanostring technology to predict surgical outcome in advanced primary high grade serous ovarian cancer (HGSOC) patients (pts). Study of the Tumor Bank Ovarian Cancer (TOC).. Journal of Clinical Oncology, 2018, 36, 5569-5569.	0.8	3
176	Low TMB as predictor for additional benefit from neoadjuvant immune checkpoint inhibition in triple-negative breast cancer.. Journal of Clinical Oncology, 2022, 40, 581-581.	0.8	3
177	Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 143-151.	1.4	2
178	Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease.. Journal of Clinical Oncology, 2021, 39, 519-519.	0.8	2
179	Reply to Y. Kawamura et al. Journal of Clinical Oncology, 2021, 39, 3090-3091.	0.8	2
180	DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status. Clinical Epigenetics, 2021, 13, 184.	1.8	2

#	Article	IF	Citations
181	Cellular and soluble immune checkpoint signaling forms PD-L1 and PD-1 in renal tumor tissue and in blood. Cancer Immunology, Immunotherapy, 2022, 71, 2381-2389.	2.0	2
182	Reply to L. OzretiÄ‡ et al. Journal of Clinical Oncology, 2011, 29, 4588-4589.	0.8	1
183	Tumour-Infiltrating Lymphocytes (TILs) in Breast Cancer: a Predictive or a Prognostic Marker?. Current Breast Cancer Reports, 2015, 7, 59-70.	0.5	1
184	In the beginning, there was chaos: A perspective on the development of immuno-oncological biomarkers. Seminars in Cancer Biology, 2018, 52, v-vi.	4.3	1
185	TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer. BMC Cancer, 2021, 21, 920.	1.1	1
186	Lack of correlation of neoantigens arising from tumor somatic mutations with tumor infiltrating lymphocytes (TILs) or survival in HER2-positive breast cancer (HER2+ BC).. Journal of Clinical Oncology, 2015, 33, 613-613.	0.8	1
187	Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial.. Journal of Clinical Oncology, 2016, 34, 11505-11505.	0.8	1
188	Influence of cytotoxic tumor-infiltrating T lymphocytes on outcome in resectable pancreatic cancer: Results from the CONKO 001 trial.. Journal of Clinical Oncology, 2017, 35, 281-281.	0.8	1
189	PIK3CA mutations in primary HER2-positive and triple negative breast cancer.. Journal of Clinical Oncology, 2013, 31, 11061-11061.	0.8	1
190	A randomized phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto).. Journal of Clinical Oncology, 2015, 33, TPS1101-TPS1101.	0.8	1
191	Signatures of mutational processes and response to neoadjuvant chemotherapy in breast cancer: A genome-based investigation in the neoadjuvant GeparSepto trial.. Journal of Clinical Oncology, 2018, 36, 574-574.	0.8	1
192	Correlation of the tumor mutational burden with the composition of the immune cell subpopulations in peripheral blood of triple-negative breast cancer patients undergoing neoadjuvant therapy with durvalumab: Results from the prospectively randomized GeparNuevo trial.. Journal of Clinical Oncology, 2019, 37, 588-588.	0.8	1
193	Polycomb Protein BMI-1 as a Potential Therapeutic Target in Mucinous Ovarian Cancer. Anticancer Research, 2022, 42, 1739-1747.	0.5	1
194	Immunological Mechanisms in Breast Cancer - from Bench to Bedside. Breast Care, 2016, 11, 93-94.	0.8	0
195	Abstract PS4-21: Comparison of risk assessment in primary ER+, HER2- Breast Cancer in a real-world data set: Classical pathological parameters vs. 12-gene molecular assay (EndoPredict). , 2021, , .		0
196	Randomized, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal b/HER2 normal breast cancer (GENEVIEVE).. Journal of Clinical Oncology, 2013, 31, TPS1138-TPS1138.	0.8	0
197	Hormone receptor-dependent regulation of ABAT and beta-alanine metabolism in breast cancer.. Journal of Clinical Oncology, 2013, 31, 11112-11112.	0.8	0
198	Prognostic score for Luminal A-like breast cancer patients.. Journal of Clinical Oncology, 2014, 32, 525-525.	0.8	0

#	Article	IF	Citations
199	Inhibition of MEK1 increases carboplatin sensitivity in ovarian cancer.. Journal of Clinical Oncology, 2014, 32, 5557-5557.	0.8	0
200	Development and validation of a new prognostic score on 4,646 patients with luminal-like breast cancer (BC) enrolled in 7 randomized prospective trials.. Journal of Clinical Oncology, 2016, 34, 529-529.	0.8	0
201	Risk assessment after neoadjuvant chemotherapy in luminal breast cancer: A prospectively planned validation of gene expression based and clinical prognostic scores in 428 residual tumor samples from two neoadjuvant clinical trials.. Journal of Clinical Oncology, 2016, 34, 522-522.	0.8	0
202	Successful generation of patient derived xenografts and patient derived 3D cultures as preclinical models for breast cancer.. Journal of Clinical Oncology, 2018, 36, 12080-12080.	0.8	0
203	Comparison of an automated cartridge-based system for mRNA assessment with central immunohistochemistry in the neoadjuvant GeparX trial.. Journal of Clinical Oncology, 2019, 37, 3075-3075.	0.8	0
204	Comparison of risk assessment in 1652 early ER positive, HER2 negative breast cancer in a real-world data set: classical pathological parameters vs. 12-gene molecular assay (EndoPredict). Breast Cancer Research and Treatment, 2022, 191, 327-333.	1.1	0
205	Abstract P5-13-36: Germline <i>BRCA</i>1/2 and other predisposition genes in high-risk early-stage HR+/HER2- breast cancer (BC) patients treated with endocrine therapy (ET) with or without palbociclib: A secondary analysis from the PENELOPE-B study. Cancer Research, 2022, 82, P5-13-36-P5-13-36.	0.4	0
206	Abstract PD2-04: Molecular plasticity of luminal breast cancer and response to CDK 4/6 inhibition - The biomarker program of the PENELOPE-B trial investigating post-neoadjuvant palbociclib. Cancer Research, 2022, 82, PD2-04-PD2-04.	0.4	0
207	Abstract P4-04-14: Immunological markers in patients with breast cancer occurring during pregnancy - Results from GBG BCP study. Cancer Research, 2022, 82, P4-04-14-P4-04-14.	0.4	0
208	Abstract PD9-07: Mdm2 gene amplification in estrogen receptor-positive breast cancer cells is associated with enhanced solid tumor growth and pronounced metastatic potential in humanized tumor mice (HTM) and a poor outcome of patients with luminal breast cancer. Cancer Research, 2022, 82, PD9-07-PD9-07.	0.4	0
209	Abstract P2-12-03: Phenotype shifting in early breast cancer with and without primary systemic treatment: A retrospective cohort analysis correlating core needle biopsies and excisional biopsies in 1250 consecutive real-world cases. Cancer Research, 2022, 82, P2-12-03-P2-12-03.	0.4	0